Market Cap | 1.36B | P/E | - | EPS this Y | -44.00% | Ern Qtrly Grth | - |
Income | -188.86M | Forward P/E | -8.38 | EPS next Y | 27.80% | 50D Avg Chg | - |
Sales | 863.49M | PEG | -0.30 | EPS past 5Y | - | 200D Avg Chg | 16.00% |
Dividend | N/A | Price/Book | 0.88 | EPS next 5Y | 12.00% | 52W High Chg | -36.00% |
Recommedations | 1.50 | Quick Ratio | 1.13 | Shares Outstanding | 696.99M | 52W Low Chg | 76.00% |
Insider Own | 52.41% | ROA | -4.73% | Shares Float | 331.18M | Beta | 1.84 |
Inst Own | 25.34% | ROE | -12.80% | Shares Shorted/Prior | 78.03M/102.16M | Price | 1.76 |
Gross Margin | 26.47% | Profit Margin | -21.87% | Avg. Volume | 3,801,127 | Target Price | 4.25 |
Oper. Margin | -37.97% | Earnings Date | Aug 1 | Volume | 2,222,674 | Change | -3.30% |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
HC Wainwright & Co. | Buy | Apr 3, 24 |
Barrington Research | Outperform | Apr 1, 24 |
Piper Sandler | Overweight | Apr 1, 24 |
HC Wainwright & Co. | Buy | Feb 28, 24 |
Barrington Research | Outperform | Feb 28, 24 |
HC Wainwright & Co. | Buy | Aug 7, 23 |
Barrington Research | Outperform | Jun 29, 23 |
HC Wainwright & Co. | Buy | May 5, 23 |
HC Wainwright & Co. | Buy | Mar 9, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
KRASNO RICHARD M | Director Director | Jan 29 | Buy | 0.9946 | 30,000 | 29,838 | 103,333 | 01/29/24 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Jan 19 | Buy | 0.9773 | 500,000 | 488,650 | 205,868,225 | 01/19/24 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Jan 18 | Buy | 0.9655 | 400,000 | 386,200 | 205,368,225 | 01/18/24 |
HSIAO JANE PH D | Vice Chairman & CTO Vice Chairman & CTO | Jan 17 | Buy | 0.95 | 150,000 | 142,500 | 27,999,880 | 01/17/24 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Jan 16 | Buy | 0.9543 | 1,000,000 | 954,300 | 204,968,225 | 01/16/24 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Jan 11 | Buy | 0.9391 | 511,531 | 480,379 | 203,968,225 | 01/11/24 |
Nabel Gary J. | Chief Innovation Off.. Chief Innovation Officer | Jan 08 | Buy | 0.92 | 216,184 | 198,889 | 107,489 | 01/10/24 |
HSIAO JANE PH D | Vice Chairman & CTO Vice Chairman & CTO | Jan 04 | Buy | 0.8726 | 150,010 | 130,899 | 27,849,880 | 01/08/24 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Jan 04 | Buy | 0.8964 | 1,500,000 | 1,344,600 | 203,456,694 | 01/08/24 |
Zerhouni Elias A. | Vice Chairman and Pr.. Vice Chairman and President | Jan 05 | Buy | 0.91 | 550,300 | 500,773 | 20,327,814 | 01/05/24 |
PFENNIGER RICHARD C JR | Director Director | Jan 05 | Buy | 0.94 | 25,000 | 23,500 | 325,000 | 01/05/24 |
Rubin Steven D | Executive VP-Adminis.. Executive VP-Administration | Nov 10 | Buy | 1.30 | 10,000 | 13,000 | 6,177,732 | 11/13/23 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Aug 17 | Buy | 1.76 | 100,000 | 176,000 | 200,956,694 | 08/18/23 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Aug 14 | Buy | 1.75 | 75,000 | 131,250 | 200,856,694 | 08/15/23 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Aug 09 | Buy | 1.82 | 100,000 | 182,000 | 200,781,694 | 08/10/23 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Aug 07 | Buy | 1.84 | 650,000 | 1,196,000 | 200,681,694 | 08/08/23 |
Nabel Gary J. | Chief Innovation Off.. Chief Innovation Officer | May 05 | Buy | 1.82 | 460,245 | 837,646 | 242,747 | 05/08/23 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Mar 22 | Buy | 1.32 | 200,000 | 264,000 | 200,031,694 | 03/23/23 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Mar 08 | Buy | 1.2 | 1,000,000 | 1,200,000 | 199,831,694 | 03/09/23 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Nov 22 | Buy | 1.49 | 300,000 | 447,000 | 198,831,694 | 11/23/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Nov 09 | Buy | 1.6 | 200,000 | 320,000 | 198,531,694 | 11/10/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Oct 27 | Buy | 1.82 | 100,000 | 182,000 | 198,331,694 | 10/28/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Oct 19 | Buy | 1.71 | 100,000 | 171,000 | 198,231,694 | 10/20/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Sep 26 | Buy | 1.8 | 50,000 | 90,000 | 197,756,694 | 09/27/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Sep 23 | Buy | 1.85 | 50,000 | 92,500 | 197,706,694 | 09/26/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Sep 22 | Buy | 1.9 | 50,000 | 95,000 | 197,656,694 | 09/23/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Sep 21 | Buy | 1.91 | 50,000 | 95,500 | 197,606,694 | 09/22/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Sep 20 | Buy | 1.94 | 50,000 | 97,000 | 197,556,694 | 09/21/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Sep 19 | Buy | 1.97 | 50,000 | 98,500 | 197,506,694 | 09/20/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Sep 02 | Buy | 2.14 | 100,000 | 214,000 | 197,256,694 | 09/06/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Aug 17 | Buy | 2.54 | 200,000 | 508,000 | 197,156,694 | 08/18/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Aug 05 | Buy | 2.28 | 350,000 | 798,000 | 196,956,694 | 08/08/22 |
Nabel Gary J. | Chief Innovation Off.. Chief Innovation Officer | Jun 22 | Buy | 2.49 | 240,000 | 597,600 | 80,000 | 06/24/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Jun 21 | Buy | 2.4 | 200,000 | 480,000 | 196,606,694 | 06/22/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Jun 16 | Buy | 2.32 | 100,000 | 232,000 | 196,406,694 | 06/17/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Jun 13 | Buy | 2.36 | 100,000 | 236,000 | 196,306,694 | 06/14/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Jun 06 | Buy | 2.8 | 100,000 | 280,000 | 196,206,694 | 06/07/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Jun 01 | Buy | 2.97 | 50,000 | 148,500 | 196,106,694 | 06/02/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | May 31 | Buy | 3.03 | 50,000 | 151,500 | 196,056,694 | 06/01/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | May 25 | Buy | 2.98 | 50,000 | 149,000 | 196,006,694 | 05/26/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | May 18 | Buy | 2.88 | 50,000 | 144,000 | 195,956,694 | 05/19/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | May 16 | Buy | 2.98 | 150,000 | 447,000 | 195,906,694 | 05/17/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | May 13 | Buy | 3 | 200,000 | 600,000 | 195,756,694 | 05/16/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | May 11 | Buy | 2.831 | 400,000 | 1,132,400 | 195,556,694 | 05/12/22 |
Zerhouni Elias A. | Vice Chairman and Pr.. Vice Chairman and President | May 09 | Buy | 2.7946 | 89,600 | 250,396 | 89,600 | 05/11/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | May 10 | Buy | 2.7839 | 400,000 | 1,113,560 | 195,156,694 | 05/11/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Mar 14 | Buy | 3.04 | 35,000 | 106,400 | 194,756,694 | 03/15/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Mar 11 | Buy | 3.13 | 100,000 | 313,000 | 194,721,694 | 03/14/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Feb 28 | Buy | 3.1 | 100,000 | 310,000 | 194,621,694 | 03/01/22 |
FROST PHILLIP MD ET AL | CEO & Chairman CEO & Chairman | Feb 25 | Buy | 3.0871 | 750,000 | 2,315,325 | 194,521,694 | 02/28/22 |